Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment
28 mai 2021 08h30 HE
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today...
AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database
25 mai 2021 06h30 HE
|
Anpac Bio, USA
SAN JOSE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (ANPC) (“AnPac Bio,” the “Company” or “we”), a biotechnology company with operations in China and the United...
Colorectal Cancer Treatment Market In North America Is Expected To Account For A Major Revenue Share During Forecast Period Till 2030: Acumen Research And Consulting
12 mai 2021 11h00 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, has recently published a report titled “Colorectal Cancer Treatment Market – Global Industry Analysis, Market Size,...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
12 mai 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve...
Novel late-stage colorectal cancer treatment proves effective in preclinical models
28 avr. 2021 09h29 HE
|
University of Minnesota Medical School
MINNEAPOLIS/ST.PAUL, April 28, 2021 (GLOBE NEWSWIRE) -- In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage...
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
13 avr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: LIXT), a clinical-stage drug discovery company developing...
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
30 mars 2021 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
17 mars 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST...
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
03 mars 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma...
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
02 mars 2021 10h30 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...